Dupixent And Vaccines Dominate As Sanofi Profits Rise
Executive Summary
Sales of Praluent and Eloctate disappointed but the promise of further growth for big-selling Dupixent augurs well for the French firm's future.
You may also be interested in...
Pfizer Continues Positive Data Readouts For JAK Inhibitor Abrocitinib In Eczema
A second Phase III JADE study showed statistically significant skin clearance and reduced pruritus in atopic dermatitis, although safety is harder to evaluate for now. A filing planned for 2020 will include results from a cross-study comparison evaluating abrocitinib versus Dupixent.
CHMP Delivers More Good News For Sanofi's Dupixent
The European committee has adopted a positive opinion for Regeneron-partnered Dupixent recommending approval to include adolescents aged 12 to 17 with atopic dermatitis.
The Challenges Facing Paul Hudson At the Helm of Sanofi
Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and research fronts and expanding its digital capabilities.